Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/104185
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWu, T.en
dc.contributor.authorZhang, X.en
dc.contributor.authorTrahair, L.en
dc.contributor.authorBound, M.en
dc.contributor.authorLittle, T.en
dc.contributor.authorDeacon, C.en
dc.contributor.authorHorowitz, M.en
dc.contributor.authorJones, K.en
dc.contributor.authorRayner, C.en
dc.date.issued2016en
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 2016; 101(12):4769-4778en
dc.identifier.issn0021-972Xen
dc.identifier.issn1945-7197en
dc.identifier.urihttp://hdl.handle.net/2440/104185-
dc.description.abstractContext: The rate of gastric emptying is an important determinant of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion, and may influence the magnitude of glucose-lowering by dipeptidyl peptidase-4 (DPP-4) inhibitors. Objective: To evaluate the effects of the DPP-4 inhibitor, vildagliptin, during intraduodenal (ID) glucose infusion at two different rates within the physiological range of gastric emptying, in type 2 diabetes. Participants and Design: A total of 16 diet-controlled type 2 diabetic patients were studied on four separate days in double-blind, randomized, fashion. On each day, either 50mg vildagliptin or placebo was given 60min prior to a 120min ID glucose infusion at 2 or 4kcal/min (ID2 or ID4). Plasma glucose and hormones were measured frequently. Results: Plasma glucose, insulin, C-peptide, glucagon, total GIP, and total and intact GLP-1 concentrations were higher during ID4 than ID2 (P<0.01 for each). Compared with placebo, vildagliptin was associated with higher intact GLP-1, insulin and C-peptide, and lower glucose and total GIP and GLP-1 (P<0.01 for each), without affecting glucagon. There were significant interactions between the rate of ID glucose and vildagliptin treatment on plasma glucose, intact and total GLP-1, and GIP (P<0.05 for each), but not insulin, C-peptide or glucagon. The reduction in glucose and the increment in intact GLP-1 after vildagliptin vs. placebo were 3.3 and 3.8 fold greater respectively, during ID4 compared to ID2. Conclusions/Interpretation: These observations warrant further study to clarify whether type 2 diabetic patients with relatively more rapid gastric emptying have greater glucose-lowering during treatment with DPP-4 inhibitors.en
dc.description.statementofresponsibilityTongzhi Wu, Xiang Zhang, Laurence G. Trahair, Michelle J. Bound, Tanya J. Little, Carolyn F. Deacon, Michael Horowitz, Karen L. Jones, and Christopher K. Rayneren
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsCopyright © 2016 by the Endocrine Societyen
dc.subjectDuodenum; Humans; Diabetes Mellitus, Type 2; Adamantane; Nitriles; Pyrrolidines; Blood Glucose; Infusions, Parenteral; Double-Blind Method; Aged; Middle Aged; Outcome Assessment (Health Care); Female; Male; Dipeptidyl-Peptidase IV Inhibitorsen
dc.titleSmall intestinal glucose delivery affects the lowering of blood glucose by acute vildagliptin in type 2 diabetesen
dc.typeJournal articleen
dc.identifier.rmid0030054008en
dc.identifier.doi10.1210/jc.2016-2813en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1066815en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/627011en
dc.identifier.pubid262574-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS14en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidWu, T. [0000-0003-1656-9210]en
dc.identifier.orcidLittle, T. [0000-0001-9814-1036]en
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
dc.identifier.orcidJones, K. [0000-0002-1155-5816]en
dc.identifier.orcidRayner, C. [0000-0002-5527-256X]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.